Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib with vinorelbine or capecitabine in HER2-positive metastatic breast cancer
2009-009885-15Phase 2Completed
- Sponsor
- GSK
- Start
- Jul 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of lapatinib in HER2-enriched breast cancer (HER2+) (2 arms), sponsored by GSK. Primary endpoint: Progression-free survival. Started Jul 2009; status: completed.
02
Drugs
lapatinib
03
Conditions
HER2-enriched breast cancer (HER2+)
Beyond the preview
Go deeper on 2009-009885-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-009885-15.